Novartis's drug reduces heart failure deaths: study
ZURICH (Reuters) - Novartis's investigational medicine RLX030 reduced the number of deaths in patients with acute heart failure, the drugmaker said on Monday based on the results of a late-stage trial.
RLX030 is form of the human hormone relaxin-2. Serelaxin acts by relaxing the blood vessels, leading to reduced stress on the heart and kidneys, the firm said in a statement.
(Reporting by Catherine Bosley)
- Deadly gun attack in eastern Ukraine shakes fragile Geneva accord |
- Japan expands army footprint for first time in 40 years, risks angering China
- Pfizer considers $100 billion bid for AstraZeneca: report
- Prosecutors extend Korea ferry captain's detention as death toll mounts |
- Rubin 'Hurricane' Carter, U.S. boxer famous in folk song, dies at 76